The Assessment of Prednisone In Remission Trial (TAPIR)
Brief Description Of Study
The purpose of this study is to collect information about 2 different recommended treatments for granulomatosis with polyangiitis (GPA, Wegener’s). We want to find out whether patients with GPA do better if they stay on a maintenance dose of 5 mg of prednisone or come off of prednisone after GPA is well-controlled. There are 5 study visits and patients will be in the study for no longer than 18 months. To join this study, patients must have a GPA diagnosis and be taking prednisone.
Detailed Study Description
Patients who are eligible may be enrolled when their daily dose of prednisone is between 5 mg and 20 mg. Everyone in this study will have their dose of prednisone decreased, unless they enter the study at 5 mg. Some patients will be randomized to decrease their prednisone to 0 mg, others to decrease or maintain their prednisone to 5 mg daily. Randomization means that the decision as to which option a person will receive is decided "by chance," not choice, like tossing a coin. Patients will complete surveys, have physical exams, and information from their medical record will be collected. This study is a project of the Vasculitis Clinical Research Consortium (VCRC), which is a network of investigators in major North American vasculitis centers. The VCRC is funded through the National Institutes of Health as a Rare Diseases Clinical Research Network with the purpose of promoting research in vasculitis.